Halozyme Therapeutics Inc. (NASDAQ:HALO) rose 1.8% during mid-day trading on Thursday . The company traded as high as $9.17 and last traded at $9.04, with a volume of 492,334 shares trading hands. The stock had previously closed at $8.88.

A number of equities research analysts have weighed in on the company. Wells Fargo & Co. restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Canaccord Genuity restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. JMP Securities lowered their price objective on Halozyme Therapeutics from $22.00 to $20.00 and set a “market outperform” rating for the company in a research note on Wednesday, March 9th. Piper Jaffray Cos. restated an “overweight” rating and set a $15.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, June 9th. Finally, Jefferies Group restated a “sell” rating and set a $6.75 price objective on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. Halozyme Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $15.68.

The stock’s market capitalization is $1.16 billion. The company has a 50-day moving average of $9.09 and a 200 day moving average of $10.06.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. During the same period in the prior year, the firm earned ($0.12) EPS. The company earned $42.50 million during the quarter, compared to analyst estimates of $29.65 million. Halozyme Therapeutics’s quarterly revenue was up 127.3% on a year-over-year basis. Equities research analysts expect that Halozyme Therapeutics Inc. will post ($1.03) earnings per share for the current year.

Several hedge funds recently made changes to their positions in HALO. Iridian Asset Management LLC CT boosted its stake in shares of Halozyme Therapeutics by 6.1% in the fourth quarter. Iridian Asset Management LLC CT now owns 8,684,184 shares of the biopharmaceutical company’s stock worth $150,497,000 after buying an additional 500,181 shares in the last quarter. BB Biotech AG boosted its stake in shares of Halozyme Therapeutics by 1.4% in the fourth quarter. BB Biotech AG now owns 7,029,832 shares of the biopharmaceutical company’s stock worth $121,827,000 after buying an additional 100,000 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Halozyme Therapeutics by 17.7% in the fourth quarter. American Century Companies Inc. now owns 396,771 shares of the biopharmaceutical company’s stock worth $6,876,000 after buying an additional 59,560 shares in the last quarter. New York State Common Retirement Fund boosted its stake in shares of Halozyme Therapeutics by 5.4% in the fourth quarter. New York State Common Retirement Fund now owns 372,785 shares of the biopharmaceutical company’s stock worth $6,460,000 after buying an additional 18,940 shares in the last quarter. Finally, California Public Employees Retirement System boosted its stake in shares of Halozyme Therapeutics by 10.2% in the fourth quarter. California Public Employees Retirement System now owns 255,600 shares of the biopharmaceutical company’s stock worth $4,430,000 after buying an additional 23,600 shares in the last quarter.

Halozyme Therapeutics, Inc is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company’s development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.